Helga Mikkelsen

Helga joined Brandon Capital in 2018.
Before joining Helga was part of the team that developed a novel treatment for respiratory disease at the Telethon Kids Institute in Perth, which subsequently became Respirion Pharmaceuticals.
Previously Helga project managed the development of anti-infective medical devices for CamStent in Cambridge, UK.
Helga undertook postdoctoral training in bacterial genetics at Imperial College London.
Helga is a board observer of OncoRes Medical and Respirion Pharmaceuticals.
Helga has both a Bachelor and Masters of Science in Chemical Engineering and Biotechnology from the Technical University of Denmark and a PhD in Microbiology from the University of Cambridge.
She is a Graduate of the Australian Institute of Company Directors.